Psoriatic Immune Response to Tildrakizumab

NCT05390515 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis Vulgaris

Interventions

DRUG: Tildrakizumab Prefilled Syringe

Sponsor

University of California, San Francisco

Collaborators

[object Object]